These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 36239883)

  • 21. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Elez E; Cruz FM; Wyrwicz L; Stroyakovskiy D; Pápai Z; Poureau PG; Liposits G; Cremolini C; Bondarenko I; Modest DP; Benhadji KA; Amellal N; Leger C; Vidot L; Tabernero J;
    N Engl J Med; 2023 May; 388(18):1657-1667. PubMed ID: 37133585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
    Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M
    ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
    Stavraka C; Pouptsis A; Synowiec A; Angelis V; Satterthwaite L; Khan S; Chauhan M; Holden C; Young S; Karampera C; Martinou M; Mills-Baldock T; Baxter M; Barry A; Eccles B; Iveson T; Shiu KK; Hill M; Abdel-Raouf S; Graham JS; Thomas A; Ross PJ
    Clin Colorectal Cancer; 2021 Dec; 20(4):342-349. PubMed ID: 34696965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
    Taniguchi H; Yamazaki K; Masuishi T; Kawakami T; Onozawa Y; Honda K; Kadowaki S; Narita Y; Tsushima T; Hamauchi S; Todaka A; Yokota T; Ando M; Mori K; Shirasu H; Yasui H; Muro K
    Oncologist; 2023 Nov; 28(11):e1108-e1113. PubMed ID: 37284901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
    Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
    Koper A; Wileński S; Śledzińska P; Bebyn M; Koper K
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10867-10877. PubMed ID: 37318592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
    Signorelli C; Calegari MA; Basso M; Anghelone A; Lucchetti J; Minelli A; Angotti L; Zurlo IV; Schirripa M; Chilelli MG; Morelli C; Dell'Aquila E; Cosimati A; Gemma D; Ribelli M; Emiliani A; Corsi DC; Arrivi G; Mazzuca F; Zoratto F; Morandi MG; Santamaria F; Saltarelli R; Ruggeri EM
    Curr Oncol; 2023 Jun; 30(6):5456-5469. PubMed ID: 37366896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
    Matsumoto T; Ikoma T; Yamamura S; Miura K; Tsuduki T; Watanabe T; Nagai H; Takatani M; Yasui H
    Sci Rep; 2023 Feb; 13(1):2433. PubMed ID: 36765099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
    Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E
    Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
    Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
    Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.
    Yoshino T; Oki E; Nozawa H; Eguchi-Nakajima T; Taniguchi H; Morita S; Takenaka N; Ozawa D; Shirao K
    ESMO Open; 2018; 3(5):e000411. PubMed ID: 30167332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.
    Doleschal B; Taghizadeh H; Lentner T; Riedl JM; Granitzer J; Morariu D; Decker J; Aichberger KJ; Webersinke G; Kirchweger P; Petzer A; Rumpold H
    ESMO Open; 2023 Dec; 8(6):102064. PubMed ID: 37977001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
    Kato T; Kagawa Y; Kuboki Y; Gamoh M; Komatsu Y; Yasui H; Satake H; Oki E; Tanioka H; Kotaka M; Makiyama A; Denda T; Goto M; Yoshino T; Yamazaki K; Soeda J; Shibuya K; Iwata M; Oba K; Yamaguchi K
    Int J Clin Oncol; 2021 Jul; 26(7):1238-1247. PubMed ID: 33928486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
    Cremolini C; Rossini D; Martinelli E; Pietrantonio F; Lonardi S; Noventa S; Tamburini E; Frassineti GL; Mosconi S; Nichetti F; Murgioni S; Troiani T; Borelli B; Zucchelli G; Dal Maso A; Sforza V; Masi G; Antoniotti C; Di Bartolomeo M; Miceli R; Ciardiello F; Falcone A
    Oncologist; 2018 Oct; 23(10):1178-1187. PubMed ID: 29739893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
    Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
    Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
    Tella SH; Foster N; Qian S; Nguyen T; Borad MJ; McWilliams RR; Alberts SR; Wee Ma W; Chakrabarti S; Fruth B; Wessling J; Hartgers M; Washburn L; Fernandez-Zapico ME; Hogenson TL; Pitot H; Jin Z; Mahipal A
    Oncologist; 2023 Oct; 28(10):917-e966. PubMed ID: 37339254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.